Meitheal Pharmaceuticals a fully integrated biopharmaceutical company based in Chicago, announced, through its parent company Nanjing King-Friend Biochemical Pharmaceutical, an exclusive licensing agreement with Tonghua Dongbao Pharmaceutical to commercialize three insulin biosimilars — insulin aspart, insulin lispro, and insulin glargine — in the US NKF has exclusive development and commercial rights for the three compounds from partner THDB and intends for Meitheal to commercialize such products in the US.
“As a fully integrated biopharmaceutical company, committed to supporting access to critical medicines, Meitheal is thrilled to be leveraging our strategic partnerships and internal capabilities to expand our growing portfolio to include insulin products,” said Tom Shea, CEO of Meitheal. “These products have the potential to improve patient access, increase treatment options and solve healthcare challenges for people living with diabetes.”
Under the terms of the agreement, Meitheal, through its parent company, will receive exclusive rights to commercialize biosimilar versions of insulin aspart, insulin lispro, and insulin glargine in the U.S. upon approval by the FDA, which is estimated to be on or around 2026. THDB and NKF entered into strategic cooperation and will be jointly responsible for the development and supply of the three products. Upon approval, THDB, NKF and Meitheal will receive royalties on all product sales in the United States.
“This collaboration reinforces the strength of NKF’s partnership with Meitheal and demonstrates our commitment to innovation and continued investment in our portfolio companies,” said Eric Tang, President of NKF. “With insulin being one of the most in-demand medicines today, we are pleased to support value-driving options to increase insulin supply for those living with diabetes.”
“This cooperation in the U.S. insulin market allows the parties to draw on each other's strengths and achieve complementary advantages, which is a perfect combination,” said Chunsheng Leng, Chairman and General Manager of THDB. “We look forward to bringing these three products one step closer to patients through this strategic partnership.”
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!